Home›Clinical trials›A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

A study testing whether a new weekly shot from Lilly, tirzepatide, can help people lose weight.

Recruiting now. Registry record last updated August 7, 2026.

Who can join
Children and teens 12 to 17, have obesity.
What you take
tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 6.5 years; your own time in it is usually shorter.
What you get
Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 3Sponsor Eli Lilly and CompanyDrug tirzepatideClass GLP-1/GIPSites 14 USEnrollment target 300

What this study is for

Primary condition: Obesity. Also studied in: Weight Gain.

Full scientific study title: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2).

Who can join

Age12 to 17SexAny

Children and teens 12 to 17, have obesity. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
  • Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
  • Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).

Key exclusion criteria

  • Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to
  • gastric bypass
  • sleeve gastrectomy
  • restrictive bariatric surgery, such as Lap-Band gastric banding, or
  • any other procedure intended to result in weight reduction.

Where this trial is enrolling

This trial has 14 sites across 8 states. Contact a site coordinator directly to start screening.

California2 sites
  • Children's Hospital Los Angeles
    Los Angeles, California
  • Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology
    Sacramento, California
Delaware1 site
  • Nemours Children's Health - Delaware
    Wilmington, Delaware
Idaho1 site
  • Medical Research Partners
    Ammon, Idaho
Illinois1 site
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois
Indiana1 site
  • Indiana University Health University Hospital
    Indianapolis, Indiana
New York2 sites
  • UBMD Pediatrics
    Buffalo, New York
  • SUNY Upstate Medical University
    Syracuse, New York
Texas5 sites
  • Driscoll Children's Hospital
    Corpus Christi, Texas
  • Epic Medical Research - DeSoto
    DeSoto, Texas
  • Valley Institute of Research - Fort Worth
    Fort Worth, Texas
  • Consano Clinical Research, LLC
    Shavano Park, Texas
  • Texas Valley Clinical Research
    Weslaco, Texas
Utah1 site
  • Alliance for Multispecialty Research, LLC
    Layton, Utah

Timeline

Started enrolling: June 3, 2024. Expected completion: December 2030. Last updated on ClinicalTrials.gov: August 7, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.